UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · IEX Real-Time Price · USD
14.15
+0.33 (2.39%)
Apr 26, 2024, 4:00 PM EDT - Market closed

UroGen Pharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Cash & Equivalents
95.8256.2245.5954.0950.21101.573721.3617.98
Short-Term Investments
41.9744.5644.7849.1597.39036.20.10.02
Cash & Cash Equivalents
137.79100.7890.37103.24147.6101.5773.221.4618
Cash Growth
36.73%11.52%-12.47%-30.05%45.32%38.76%241.14%19.23%-
Receivables
15.4412.711.727.050000.080
Inventory
5.674.334.831.96000.320.110
Other Current Assets
10.2811.17.483.361.030.670.960.41.14
Total Current Assets
169.19128.91114.39115.62148.63102.2474.4722.0419.13
Property, Plant & Equipment
2.363.753.154.24.710.950.810.740.26
Long-Term Investments
4.730.220.92.1248.780.050.030.020
Other Long-Term Assets
2.042.741.310.070.260.320.240.250
Total Long-Term Assets
9.136.715.366.3953.751.321.081.020.26
Total Assets
178.31135.62119.75122.01202.39103.5675.5523.0619.39
Accounts Payable
16.5412.3812.110.0211.198.544.441.881.73
Deferred Revenue
0000000.6500
Other Current Liabilities
14.6711.5310.2811.418.34.931.951.260.51
Total Current Liabilities
31.2123.9222.3821.4419.4813.477.043.142.24
Long-Term Debt
99.499.120.41.52.60000
Other Long-Term Liabilities
112.92101.9488.562.720003.610.87
Total Long-Term Liabilities
212.31201.0688.954.212.6003.610.87
Total Liabilities
243.52224.98111.3325.6522.0913.477.046.753.11
Total Debt
99.499.120.41.52.60000
Debt Growth
0.27%24805.28%-73.41%-42.51%-----
Retained Earnings
-679.35-577.1-467.32-356.5-228.02-122.87-47.21-27.21-25.27
Comprehensive Income
0.01-0.11-0.030.270.280000
Shareholders' Equity
-65.21-89.368.4196.36180.390.0968.5216.3116.28
Net Cash / Debt
38.391.6589.97101.75145101.5773.221.4618
Net Cash / Debt Growth
2221.28%-98.16%-11.58%-29.83%42.75%38.76%241.14%19.23%-
Net Cash Per Share
1.330.074.034.677.066.457.539.317.82
Working Capital
137.97104.9992.0194.18129.1588.7867.4418.916.89
Book Value Per Share
-2.26-3.920.384.428.785.727.057.077.08
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).